Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665693 | 1.00 | CA1 (0.37) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL9383516 | 0.89 | CA1 (0.43) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL27414290 | 0.88 | LTA4H (0.36) | CA1CA2ZDHHC7LTA4HSLC1A1 | |
| SCHEMBL27340491 | 0.88 | LTA4H (0.36) | CA1CA2ZDHHC7LTA4HSLC1A1 | |
| Hydrochloric Acid SCHEMBL9383511 | 0.87 | CA1 (0.42) | CA1CA2ZDHHC7LTA4HDPP7 | |
| Hydrochloric Acid SCHEMBL3623148 | 0.87 | CA1 (0.42) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL16330498 | 0.85 | ZDHHC7 (0.45) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL27405459 | 0.83 | ZDHHC7 (0.48) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL27405457 | 0.83 | ZDHHC7 (0.48) | CA1CA2ZDHHC7LTA4HDPP7 | |
| SCHEMBL7023567 | 0.82 | DDAH1 (0.39) | CA1CA2LTA4HDPP7DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097236-A4 | STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1109928-A4 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6649387-B2 | From dipeptides | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-18 | — | — | US | disclosed |
| US-6515170-B1 | The present invention concerns an enzymatic oxidative deamination process to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. | BRISTOL-MYERS SQUIBB CO. | 2003-02-04 | — | — | US | disclosed |
| US-6486331-B2 | FOR STEREOSELECTIVE ENZYMATIC REDUCTIVE AMINATION FOR CONVERSION OF 5-(1,3-DIOXOLAN-2-YL)-2-OXO-PENTANOIC ACID TO 5-(1,3-DIOXOLAN-2-YL)-2S-AMINO-PENTANOIC ACID IN YEAST CULTURES | BRISTOL-MYERS SQUIBB CO. | 2002-11-26 | — | — | US | disclosed |
| US-6468781-B1 | USING RECOMBINANT METHYLOTROPHIC YEAST HOST CELL CAPABLE OF PRODUCING BOTH PHENYLALANINE DEHYDROGENASE AND FORMATE DEHYDROGENASE | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-20020049342-A1 | Substituted alkylketo compounds and process | HANSON RONALD L (US) | 2002-04-25 | — | — | US | disclosed |
| US-6329542-B1 | GLYCINAMIDE DERIVATIVE IS REACTED WITH DIOXOLANE COMPOUND, TREATING INTERMEDIATE WITH WATER AND REFLUXING TO GIVE DIOXOLANE PENTANOIC ACID COMPOUND WHICH IS TREATED TO EXCHANGE THE DIOXOLANE ACETAL WITH A DIMETHOXY ACETAL, ESTERIFICATION | BRISTOL-MYERS SQUIBB CO. | 2001-12-11 | — | — | US | disclosed |
| US-6329542-B1 | GLYCINAMIDE DERIVATIVE IS REACTED WITH DIOXOLANE COMPOUND, TREATING INTERMEDIATE WITH WATER AND REFLUXING TO GIVE DIOXOLANE PENTANOIC ACID COMPOUND WHICH IS TREATED TO EXCHANGE THE DIOXOLANE ACETAL WITH A DIMETHOXY ACETAL, ESTERIFICATION | BRISTOL-MYERS SQUIBB CO. | 2001-12-11 | — | — | US | disclosed |
| US-6261810-B1 | PREPARING SPECIFIC AMINO LACTAM COMPOUND BY CONTACTING DIPEPTIDE MONOMER WITH AMINOTRANSFERASE IN PRESENCE OF ALPHA-KETOGLUTARATE; FORMING CHEMICAL INTERMEDIATES OF INHIBITORS OF ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-1109928-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6248882-B1 | VIA DIOXOLANE INTERMEDIATES | BRISTOL-MYERS SQUIBB CO. | 2001-06-19 | — | — | US | disclosed |
| EP-1097236-A1 | STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6166227-A | Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via novel dioxolanes | BRISTOL-MYERS SQUIBB CO. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6140088-A | Stereoselective reductive amination of ketones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000014265-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000004179-A1 | STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049342-A1 | Substituted alkylketo compounds and process | DAO, KMO, BCAT1 | CA1 2230/4885CA2 2478/4885ZDHHC7 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.